Consensus Fennec Pharmaceuticals Inc. Toronto S.E.

Equities

FRX

CA31447P1009

Market Closed - Toronto S.E. Other stock markets 20:59:59 17/07/2024 BST			5-day change	1st Jan Change
9.1 ^CAD	-0.55%		+12.62%	-39.97%

07-02	MT Newswires Weekend Stocks To Watch: BCE; Bitfarms; Fennec; GreenPower; Hut 8; Restaurant Brands; Sigma Lithium; Solaris	MT
07-01	Fennec Pharmaceuticals Chief Operating Officer Adrian Haigh Steps Down	MT

Evolution of the average Target Price on Fennec Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

d98fdb632c92182c00cda96575e5fc65.f98dLnPGg9xMlMtGM70wI7mD6cgCJ2vyEd5p4xV5lVU.EY5XXTGEyZsIrYA2YpBUS9Hx0Z54bRyhXJALomQj5TgwsG54HJL5qBvbng~e4d099fc45a5117048b84f8707e44370

Analyst Recommendations on Fennec Pharmaceuticals Inc.

HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating	05-15	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	04-19	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	04-17	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	04-05	MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating	04-04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	04-03	MT
HC Wainwright Adjusts Price Target on Fennec Pharmaceuticals to $17 From $18, Maintains Buy Rating	04/08/23	MT
Cantor Fitzgerald Adjusts Fennec Pharmaceuticals' Price Target to $16 From $12	06/04/23	MT
Wedbush Adjusts Fennec Pharmaceuticals Price Target to $16 From $17, Maintains Outperform Rating	30/03/23	MT
Wedbush Lowers Fennec Pharmaceuticals' Price Target to $17 From $19, Maintains Outperform Rating	25/01/23	MT
Cantor Fitzgerald Upgrades Fennec Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $12 From $9	22/11/22	MT
HC Wainwright Adjusts Fennec Pharmaceuticals' Price Target to $18 From $14, Keeps Buy Rating	20/10/22	MT
Maxim Adjusts Fennec Pharmaceuticals' Price Target to $15 from $10, Maintains Buy	29/09/22	MT
Wedbush Adjusts Fennec Pharmaceuticals Price Target to $19 From $11, Maintains Outperform Rating	26/09/22	MT
Capital One Starts Fennec Pharmaceuticals at Overweight With $11 Price Target	07/09/22	MT
Craig-Hallum Assumes Fennec Pharmaceuticals at Buy With $14 Price Target	08/08/22	MT
Wedbush Maintains Outperform, Raises Fennec Pharmaceuticals' TP to US$11	12/05/22	MT
Wedbush Lifts Price Target for Fennec Pharmaceuticals to $11 From $10, Maintains Outperform Rating	12/05/22	MT
Wedbush Maintains Outperform, US$10 TP on Fennec Pharmaceuticals After Q4, Pedmark Update	28/02/22	MT
Wedbush Lifts Price Target for Fennec Pharmaceuticals to $10 From $9, Maintains Outperform Rating	28/02/22	MT
Maxim Group Adjusts Price Target on Fennec Pharmaceuticals to $10 From $12, Keeps Buy Rating	01/12/21	MT
Craig-Hallum Adjusts Price Target on Fennec Pharmaceuticals to $14 From $19, Maintains Buy Rating	30/11/21	MT
Wedbush Maintains Outperform, US$9 TP, on Fennec Pharmaceuticals After Second Pedmark Delay	29/11/21	MT
Wedbush Adjusts Price Target on Fennec Pharmaceuticals to $9 From $12 on Pedmark Approval Delay; Outperform Rating Kept	29/11/21	MT
FENNEC PHARMACEUTICALS : Wedbush Lifts Price Target for Fennec Pharmaceuticals to $12 From $11, Maintains Outperform Rating	10/08/21	MT